Disclaimer: All proprietary content on Physicians Now is exclusively owned by Physicians Now. All RSS feed content is owned by the respective 3rd party website.

image

Summary: Eisai Inc will present studies on Dayvigo (lemborexant) at the American Academy of Neurology Annual Meeting, focusing on its benefits for insomnia patients including improved daytime alertness and sleep quality, particularly in older adults. Research will also cover the transition from Z-drugs to Dayvigo, showcasing its effectiveness in sleep initiation and maintenance by inhibiting orexin neurotransmission. Dayvigo has been approved in over 15 countries. 

Key Takeaways: 

  • Eisai Inc will present new data on Dayvigo at the American Academy of Neurology Annual Meeting. 
  • Dayvigo has been approved for the treatment of insomnia in more than 15 countries, including Japan, the United States, Canada, Australia, and several countries in Asia.
  • Topics include Dayvigo’s impact on daytime alertness in individuals with insomnia, its efficacy in older adults, and the process for transitioning patients from Z-drugs to Dayvigo.

Eisai Inc announced it will present data on its insomnia dual orexin receptor antagonist Dayvigo (lemborexant) at the American Academy of Neurology annual meeting

Dayvigo (lemborexant) is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Presentations will include a study on the effects of lemborexant on daytime alertness in individuals with insomnia, analyzing how this treatment can improve overall daily functioning. Another session will cover the efficacy of lemborexant in older adults, particularly its impact on sleep duration and quality, highlighting response rates and remission statistics. Additionally, findings from two studies will be discussed that focus on the transition process for patients switching from Z-drugs to lemborexant.

Presentation details are as follows:

  • Impact of Lemborexant on Daytime Sleepiness/Alertness in Subjects with Insomnia Disorder: Poster presentation number 014, Session P8: Sleep 1, Tuesday, April 16, 5:30-6:30 pm MDT
  • Lemborexant Treatment in Older Adults with Insomnia and Objective Short Sleep: Rates of Response and Remission: Poster presentation number 015, Session P8: Sleep 1, Tuesday, April 16, 5:30-6:30 pm MDT
  • Transitioning Between Z-drugs and Lemborexant: Data from Two Studies: Poster presentation number 016, Session P8: Sleep 1, Tuesday, April 16, 5:30-6:30 pm MDT

Dayvigo works by inhibiting orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). In individuals with normal daily sleep-wake rhythms, orexin signaling is believed to promote periods of wakefulness. In individuals with sleep-wake disorders, it is possible that orexin signaling which regulates wakefulness is not functioning normally, suggesting that inhibiting inappropriate orexin signaling may enable initiation and maintenance of sleep. 

It has been approved for the treatment of insomnia in over 15 countries including Japan, the United States, Canada, Australia, and countries in Asia.

The meeting will be held in Denver and virtually from April 13-18.

Photo 111951804 © Vivilweb | Dreamstime.com

Do you think you may suffer from Insomnia and live in Florida, California or New York?

If so, please consider scheduling a proper virtual online Insomnia and Anxiety diagnosis with one of our physicians. Although we have an online ADHD and Anxiety diagnosis tool, a proper diagnosis from a Board-Certified Medical Doctor will help you know for sure. If appropriate, a customized treatment program will be recommended at the conclusion of that initial visit.

Call Now Button